Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amneal Pharmaceuticals Inc
(NY:
AMRX
)
5.870
UNCHANGED
Last Price
Updated: 7:00 PM EST, Dec 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amneal Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
April 10, 2023
Via
Benzinga
Expert Ratings for Amneal Pharmaceuticals
March 29, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 14, 2023
Tuesday's morning session saw 84 companies set new 52-week lows.
Via
Benzinga
Amneal Seeks FDA Approval For Its Parkinson's Candidate
September 01, 2022
Via
Benzinga
Amneal Pharma Posts Mixed Q2 Earnings, Cuts Profit Outlook For 2022
August 05, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
March 06, 2023
On Monday, 36 companies set new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
March 01, 2023
Via
Benzinga
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
January 25, 2023
Intercept entered a deal with Amneal, likely lining up a series of new settlements.
Via
Investor's Business Daily
Amneal Pharmaceuticals: Q3 Earnings Insights
November 04, 2022
Amneal Pharmaceuticals (NYSE:AMRX) reported its Q3 earnings results on Friday, November 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap: Amneal Pharmaceuticals Q2 Earnings
August 05, 2022
Amneal Pharmaceuticals (NYSE:AMRX) reported its Q2 earnings results on Friday, August 5, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap: Amneal Pharmaceuticals Q1 Earnings
May 04, 2022
Amneal Pharmaceuticals (NYSE:AMRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For November 4, 2022
November 04, 2022
Companies Reporting Before The Bell • Sprott (NYSE:SII) is likely to report quarterly earnings at $0.49 per share on revenue of $49.95 million. • Telefonica (NYSE:TEF) is likely to report earnings for...
Via
Benzinga
Earnings Outlook For Amneal Pharmaceuticals
November 03, 2022
Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Friday, 2022-11-04. Here's what investors need to know before the announcement. Analysts estimate that Amneal...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 31, 2022
Gainers
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
August 11, 2022
On Thursday, 22 companies reached new 52-week lows.
Via
Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For August 5, 2022
August 05, 2022
Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.
Via
Benzinga
Amneal Pharmaceuticals's Earnings: A Preview
August 04, 2022
Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Amneal...
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Amneal Pharmaceuticals's Earnings Outlook
May 03, 2022
Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
21 Stocks Moving in Monday's Pre-Market Session
April 18, 2022
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) shares rose 16.2% to $2.51 in pre-market trading. Mullen Automotive announced plans to begin construction for EV battery pack...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
April 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Amneal Scores Second US Biosimilars Approval With Alymsys In Oncology
April 14, 2022
The FDA approved Amneal Pharmaceuticals Inc (NYSE: AMRX) Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin. The product...
Via
Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
April 01, 2022
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...
Via
Benzinga
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
March 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Amneal Pharmaceuticals's Return On Capital Employed Insights
March 08, 2022
Amneal Pharmaceuticals (NYSE:AMRX) brought in sales totaling $536.90 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 235.83%, resulting...
Via
Benzinga
Amneal Pharma's Q4 Earnings Fall Short Of Expectations, Sees FY22 Sales Growth Of 7%
March 02, 2022
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q4 revenue of $537 million, an increase of 5% Y/Y, marginally missing the consensus of $537.35 million. The increase was...
Via
Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
March 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label...
Via
Benzinga
Recap: Amneal Pharmaceuticals Q4 Earnings
March 02, 2022
Amneal Pharmaceuticals (NYSE:AMRX) reported its Q4 earnings results on Wednesday, March 2, 2022 at 06:00 AM. Here's what investors need to know about the announcement....
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.